Myria Biosciences AG

Myria Biosciences aims to reshape drug discovery with synthetic intelligence to engineer natural-product inspired chemical compounds for pharma and biotech challenges.

The company's GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform combines synthetic biology and artificial intelligence into a synthetic intelligence approach that allows therapeutic compound design and biological production far beyond what nature's evolution has provided.
Myria is unlocking new chemical space and generating optimized molecular candidates with unprecedented speed and precision for unmet medical needs.